tiprankstipranks

ImmuPharma Extends Warrants in Incanthera, Enhancing Investment Potential

Story Highlights

An update from ImmuPharma ( (GB:IMM) ) is now available.

ImmuPharma PLC has announced an extension of warrants in Incanthera to 30 September 2025, allowing the company to potentially benefit from investment gains if Incanthera’s business development positively impacts its share price. This agreement, which includes a profit-sharing mechanism, is seen as advantageous for both companies and has been treated as a related party transaction due to the involvement of Tim McCarthy, who holds positions in both companies.

More about ImmuPharma

ImmuPharma PLC is a specialty biopharmaceutical company focused on discovering and developing peptide-based therapeutics. Its portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives, with a lead program, P140, targeting Systemic Lupus Erythematosus (SLE) and Chronic Idiopathic Demyelinating Polyneuropathy (CIDP).

YTD Price Performance: 145.00%

Average Trading Volume: 10,519,224

Technical Sentiment Signal: Hold

Current Market Cap: £14.69M

For a thorough assessment of IMM stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App